e-ISSN: 2320-4230, p-ISSN: 2961-6085

Journal of Drug Discovery and Therapeutics

Available Online at www.jddt.in

CODEN: - JDDTBP (Source: - American Chemical Society)

Volume 14, Issue 3; 2026, 267-281

Artificial Intelligence in Antibiotic Discovery

Kajal Gurow[1], Anuj Sharma[1], Avdesh Meena[1], Abhishek Meena[1], Pratyaksh Saini[1], Uttam Singh Baghel[1]

[1]Gurukul Pharmacy College, Ranpur, Kota, Rajasthan

Received: 16-03-2026/ Revised: 17-04-2026/ Accepted: 20-05-2026

Corresponding author: Dr. Uttam Singh Baghel

Conflict of interest: No conflict of interest.

Abstract:

Antimicrobial resistance (AMR) is increasing rapidly, making many old antibiotics less effective. Because traditional methods of discovering new antibiotics are slow, expensive, and often unsuccessful, new approaches are needed. Artificial intelligence (AI) is emerging as a powerful tool that can speed up and improve the process of antibiotic discovery. This review explains how AI techniques like machine learning, deep learning, natural language processing, and generative models are used to discover new antibiotics and antimicrobial peptides (AMPs). AI helps in important steps such as identifying drug targets, screening compounds, designing new molecules, improving drug properties, and predicting resistance.

The article also discusses how AI can work together with fields like synthetic biology and nanotechnology to develop advanced treatments, including personalized therapies. However, challenges such as limited data, bias in algorithms, and difficulties in applying research to clinical practice still exist.

Overall, combining AI with laboratory research offers a promising and efficient way to develop new antibiotics and fight antimicrobial resistance.

Keywords: Artificial intelligence; Antimicrobial resistance; Antibiotic discovery; Machine learning; Deep learning; Generative models; Antimicrobial peptides

Introduction

Antimicrobial Resistance (AMR) has become one of the most serious global health problems. Many bacteria are now resistant to commonly used antibiotics, making infections more difficult to treat. As a result, the effectiveness of existing antibiotics has decreased, leading to a higher risk of severe illness, complications, and death.

The traditional process of discovering new antibiotics is slow, costly, and time-consuming. Developing a new antibiotic may take more than 10 years, and many drug candidates fail during different stages of research and clinical development. In addition, many pharmaceutical companies show limited interest in antibiotic research because antibiotics generally provide lower profits compared to medicines used for chronic diseases. Due to these reasons, the development of new antibiotics has declined significantly **(1)**

To address this growing problem, advanced and innovative approaches are required. Artificial Intelligence (AI) has emerged as a

powerful tool in modern drug discovery. AI can rapidly analyze large volumes of biological and chemical data and assist researchers in multiple stages of antibiotic development, including drug target identification, compound screening, and prediction of drug safety and effectiveness.

AI technologies such as machine learning and deep learning can improve the speed, accuracy, and overall success rate of antibiotic discovery. These methods also help scientists design novel drug molecules and better understand how bacteria develop resistance to antibiotics.

This article highlights the important role of AI in antibiotic discovery, including its applications in the development of small-molecule antibiotics and antimicrobial peptides. It also explains how AI can help overcome the major challenges associated with AMR **(2)**



Figure 1. Relative comparison between the conventional methods of antibiotic discoveries and AI-based methods. The figure points out the most important parameters that affect the development of antibiotics, such as time, cost, scalability, chemical and biological space exploration, resistance management and optimization, success rate and reliance on laboratory workflow or computational workflow.

Conventional methods are built around longer timescales, greater expenses, lack of scalability and intensive reliance on wet-lab testing, whereas AI-based methods are much quicker, cheaper, more scalable, and allow better exploration of chemical and biological space, are better at being optimized without resistance, and have higher overall success rates through computationally inspired decision-making.

Role and Potential of AI

Artificial Intelligence (AI) includes a wide range of computational techniques such as machine learning (ML), deep learning (DL), natural language processing (NLP), and reinforcement learning. These technologies allow computers to learn from data and perform tasks that traditionally required human intelligence.

In the field of antibiotic discovery, AI has significantly improved conventional processes such as literature mining, compound screening, and prediction of drug properties. These advancements have helped researchers manage the complex and large-scale nature of drug discovery pipelines more effectively through innovative computational approaches **(3)**

One of the major advantages of AI is its ability to integrate and analyze large datasets containing chemical information, biological assay results, genomic data, and pharmacokinetic parameters. AI algorithms can model complex biological interactions and simulate molecular dynamics, allowing more accurate prediction of drug efficacy and toxicity compared to traditional heuristic methods. These improvements support faster identification of lead compounds with better activity, improved safety profiles, and more reliable decision-making during the drug development process **(4)**

In addition, machine learning models, particularly deep neural networks, have shown excellent performance in predicting important molecular properties such as solubility, stability, and binding affinity. These properties are essential for optimizing antibiotic candidates.

The integration of AI with high-throughput experimental techniques and automated synthesis platforms has the potential to create fully integrated drug discovery pipelines. This enables rapid cycles of molecule design, testing, and optimization, thereby reducing the time between initial drug discovery and clinical application. Such a combination not only accelerates antibiotic discovery but also reduces development costs, which is important for reviving antibiotic research and combating Antimicrobial Resistance (AMR) **(5)** .

Scope and Objectives of AI-Driven Antibiotic Discovery

The application of Artificial Intelligence (AI) in antibiotic discovery has emerged as a rapidly advancing and multidisciplinary field. AI techniques are extensively utilized in the discovery and optimization of antimicrobial peptides (AMPs), small-molecule antibiotics, virtual screening processes, and mechanistic prediction studies. Antimicrobial peptides represent a promising class of therapeutic agents due to their broad-spectrum antimicrobial activity and comparatively lower tendency to induce resistance. Consequently, they have become important targets for AI-assisted design and optimization approaches **(4)**

Simultaneously, AI-driven methodologies are being widely applied in the development of small-molecule antibiotics. Computational approaches such as molecular docking, pharmacokinetic modeling, and de novo molecular design are increasingly employed to predict drug efficacy, optimize molecular properties, and accelerate the identification of potential antibiotic candidates.

Interdisciplinary collaboration plays a crucial role in the long-term advancement of AI-assisted antibiotic research. The integration of expertise from microbiology, computational biology, medicinal chemistry, data science, and clinical pharmacology contributes to the development of robust algorithms supported by strong biological understanding. Such collaborations enhance the reliability and translational potential of AI-based discoveries **(6)**

In addition, open-data sharing has become an essential component of modern antibiotic research. The availability of high-quality screening datasets enables the effective training and validation of predictive AI models, thereby improving their generalizability, accuracy, and practical

applicability across diverse biological systems.

Despite its significant potential, AI-based antibiotic discovery faces several challenges, including the heterogeneity and limited availability of labeled datasets, algorithmic bias, and issues related to model interpretability. These limitations may affect the reliability and reproducibility of computational predictions.

Future developments in this field are expected to focus on improved data curation strategies, the development of Explainable Artificial Intelligence (XAI) systems, and the integration of wet-laboratory validation studies to confirm computational findings. The strategic implementation of AI not only has the potential to accelerate the antibiotic discovery process but also to support the development of personalized and adaptive therapeutic solutions for effectively combating antimicrobial resistance (AMR) **(7)**



Figure 2. Theoretical demonstration of AI in the contemporary antibiotic discovery. The framework depicts the combination of antimicrobial peptides (AMPs) and small-molecule antibiotics with AI-based methods like DL, virtual screening, and transfer learning. The main issues such as the lack of data, algorithmic bias, and model interpretability are mentioned, and the future trends and solutions to them such as better

data curation, explainable AI, and wet-lab validation are given. The figure also highlights the necessity of interdisciplinary teamwork in the areas of microbiology, medicinal chemistry, computational biology, pharmacology and systems biology with the aid of sophisticated AI tools and platforms to hasten and streamline the process.

AI Technologies and Methodologies in Antibiotic Discovery

Machine Learning (ML) and Deep Learning (DL) Techniques

The application of Artificial Intelligence (AI) in antibiotic discovery is a broad and rapidly growing field. It includes the identification of antimicrobial peptides (AMPs), the discovery of small-molecule antibiotics, virtual screening, and the prediction of resistance mechanisms. AI-driven discovery programs also focus on small-molecule antibiotics, where computational models are applied in molecular docking, pharmacokinetic profiling, and de novo molecular design.

Advanced deep learning (DL) architectures have significantly improved tasks such as ligand–receptor binding affinity prediction, de novo drug design, and resistance mechanism modeling. These models are capable of processing extremely large chemical libraries, thereby enabling efficient virtual screening pipelines in which highly promising compounds can be selected from millions of candidates **(8)**

Furthermore, transfer learning and multi-task learning approaches allow AI systems to apply knowledge gained from related problems to new tasks, improving performance in data-limited situations, which are common in antibiotic research. These AI methodologies are widely used for both small-molecule antibiotics and AMPs, expanding therapeutic opportunities and improving biological understanding **(9)**

Data Sources and Preprocessing for AI Models

The success of AI-based antibiotic discovery largely depends on the quality, diversity, and reliability of the input data. Important data sources include:

- Chemical libraries containing structural and functional annotations
- Multi-omics datasets such as genomics, transcriptomics, and proteomics of bacterial pathogens
- Phenotypic screening datasets measuring antimicrobial activity and cytotoxicity

Before being used in AI models, these datasets require preprocessing steps such as integration, normalization, and standardization to ensure consistency and relevance.

However, several data-related challenges exist, including:

- Noisy or incomplete datasets,
- Missing values
- Class imbalance, where active compounds are much fewer than inactive compounds

To overcome these limitations, researchers employ careful data curation, augmentation strategies, and algorithms designed to handle imbalanced datasets effectively **(7).**

Phenotypic data obtained from high-throughput screening platforms can also be improved using AI-based annotation and standardization tools, increasing their usefulness for model training. Techniques such as:

- Synthetic Minority Over-Sampling Technique (SMOTE)
- Generative Adversarial Networks (GANs)

are commonly used to increase the number of positive training samples.

Additionally, large language models such as BioGPT and ChemBERTa help researchers identify chemical–biological relationships, generate mechanistic hypotheses, and predict retrosynthetic pathways from scientific literature. These tools accelerate candidate molecule design and reduce the burden of manual hypothesis testing in antimicrobial research **(10)**

Generative Models and De Novo Drug Design

Generative AI models have emerged as powerful tools for designing novel antibiotic candidates with desired pharmacological properties. Architectures such as:

- Variational Autoencoders (VAEs)
- Generative Adversarial Networks (GANs)
- Reinforcement learning-based frameworks

allow researchers to explore extremely large chemical spaces beyond existing compound libraries **(11).**

These methods support multi-objective optimization, enabling simultaneous improvement of multiple parameters, including:

- Antimicrobial potency
- Cytotoxicity
- Synthetic feasibility
- Pharmacokinetic properties

One important example is the SyntheMol pipeline, which combines Monte Carlo Tree Search algorithms with graph neural networks to generate optimized small-molecule antibiotics.

Generative AI has also been successfully applied to antimicrobial peptide (AMP) design. These models explore vast peptide sequence spaces to identify candidates with high antimicrobial activity and low toxicity.

By continuously refining predictions using experimental feedback, generative AI accelerates lead optimization and enables the discovery of chemically novel antibiotic compounds **(12)**

Another important computational approach is Molecular Dynamics (MD) simulation, which studies the movement and interaction of atoms and molecules using Newtonian mechanics. MD simulations help researchers understand:

- Molecular interactions
- Thermodynamic properties
- Dynamic behavior of biological systems

Modern MD simulations are now supported by scalable cloud-based High-Performance Computing (HPC) and AI platforms, enabling large-scale computational studies.

In addition, Quantum Machine Learning (QML) is gaining attention for studying quantum-chemical interactions between antibiotics and their biological targets. QML has the potential to enable ultrafast virtual screening and improve understanding of molecular interactions at the atomic level.

Differentiating Bioinformatics Pipelines and AI Models in Antibiotic Discovery

AI-based antibiotic discovery does not function independently; rather, it operates as part of a larger bioinformatics ecosystem. Therefore, it is important to distinguish between bioinformatics tools and AI models.

Bioinformatics Pipelinesp

Bioinformatics pipelines are mainly responsible for:

- Data generation
- Data annotation
- Data preprocessing
- Organization of biological information

Examples include:

- Genome sequencing and annotation platforms
- Protein structure prediction tools such as AlphaFold2 and RoseTTAFold
- Molecular docking software such as GNINA
- Biological databases like Protein Data Bank (PDB), ChEMBL, BindingDB, and AMP repositories

These tools convert raw biological and chemical data into structured machine-readable formats such as:

- Protein structures
- Molecular graphs
- Binding scores
- Activity labels
- AI Models
- In contrast, AI models use these processed datasets to:
- Learn biological and chemical patterns
- Predict antimicrobial activity
- Identify drug targets
- Generate novel molecular structures
- Optimize lead compounds

Thus, bioinformatics pipelines provide the foundational data infrastructure, while AI models perform predictive and generative tasks that accelerate antibiotic discovery **(9)**

AI Applications in Small-Molecule Antibiotic Discovery

Virtual Screening and Molecular Docking Enhancements

Artificial Intelligence (AI) has greatly improved virtual screening methods used in the early stages of drug discovery. Machine learning (ML) models enhance molecular docking simulations by accurately predicting ligand–receptor interactions. This helps researchers identify compounds with strong binding affinity toward bacterial targets while reducing the number of unsuitable candidates **(13)**

AI-driven QSAR (Quantitative Structure–Activity Relationship) models can rapidly rank compounds according to their predicted antimicrobial activity. As a result, researchers can focus only on the most promising molecules for in vitro validation studies. In addition, combining molecular docking with AI-based ADME (Absorption, Distribution, Metabolism, and Excretion) and toxicity prediction enables the identification of compounds with favorable drug-like properties and minimal side effects. Such in silico approaches also help evaluate pharmacokinetic behavior and interaction energies, thereby reducing the cost and time associated with experimental testing **(14)**

A notable example of this approach involved the screening of curcuminoid derivatives against outer membrane protein targets of Acinetobacter baumannii (A. baumannii). AI-assisted computational methods successfully identified lead compounds with favorable binding energies and pharmacokinetic profiles. These findings were later supported by microbiological assays, demonstrating the efficiency and reliability of AI-guided screening strategies in antibiotic discovery **(12)**

Optimization of Drug-Likeness and Pharmacokinetics

Optimization of drug-likeness and pharmacokinetic properties is an important stage in antibiotic development, especially because bacterial membranes and host toxicity create additional challenges. AI models play a major role in predicting important molecular properties such as solubility, stability, and metabolism during the early stages of drug development. Early prediction of these parameters helps reduce the chances of failure in later stages **(15)**

Deep learning (DL) and graph-based modeling techniques are widely used to analyze molecular characteristics and predict possible adverse effects or off-target

interactions. These computational approaches support iterative lead optimization, thereby improving the bioavailability, feasibility, and overall effectiveness of antibiotic candidates. Furthermore, AI systems can predict potential drug interactions and emerging resistance mechanisms by modeling bacterial target interactions and metabolic pathways.

When integrated into a computational–experimental workflow, these AI-based optimization strategies can significantly reduce attrition rates and accelerate the progression of promising drug candidates into preclinical testing stages **(16)**

The AI Discovery Antibiotics

1. Halicin: Discovery of a New Broad-Spectrum Antibiotic
2. Abaucin: ML-Guided Narrow-Spectrum Antibiotic Discovery
3. Phage Lysins: AI-Guided Discovery

Halicin: Discovery of a New Broad-Spectrum Antibiotic (6)

What is Halicin?

Halicin is a potent broad-spectrum antibiotic candidate rediscovered by researchers at Massachusetts Institute of Technology using a custom deep learning model. The discovery of Halicin is considered a major pharmacological and clinical milestone because it represents one of the first successful examples of a novel antibiotic identified through an end-to-end AI-driven approach.

A deep neural network (NN) trained on a large dataset of chemical structures and experimentally measured antibacterial activity was used to discover Halicin. The model learned complex structure–activity relationships along with traditional QSAR (Quantitative Structure–Activity Relationship) features. It was then applied to virtually screen drug libraries containing more than 100 million molecules. The AI system specifically searched for compounds that could inhibit bacterial growth while also being structurally different from existing antibiotics. This strategy increased the possibility of identifying molecules with completely new mechanisms of action.

Halicin emerged as one of the most promising candidates from the virtual screening process. Experimental studies confirmed its strong antibacterial activity against several multidrug-resistant (MDR) pathogens, including:

i. Tuberculosis-causing Mycobacterium tuberculosis
ii. Acinetobacter baumannii
iii. Clostridioides difficile

Further in vivo studies using murine (mouse) infection models demonstrated effective bacterial clearance with minimal toxicity.

Mechanistic investigations later revealed that Halicin disrupts the proton motive force of bacterial cell membranes. This mechanism differs significantly from those of conventional antibiotics, making Halicin a promising candidate against antibiotic-resistant bacteria.



Abaucin: ML-Guided Narrow-Spectrum Antibiotic Discovery (17)

Abaucin was discovered using a machine learning (ML)-based virtual screening pipeline specifically trained on activity data against Acinetobacter baumannii.

Unlike broad-spectrum antibiotic discovery approaches, this AI model was designed to identify compounds that selectively target A. baumannii while minimizing harmful effects on beneficial microbiota. The screening process combined:

i. Molecular descriptors
ii. Docking scores
iii. Predicted permeability across the bacterial outer membrane
iv. Using these parameters, the AI model filtered thousands of compounds and identified the most promising candidates.
v. Subsequent in vitro testing demonstrated that Abaucin showed high activity against multidrug-resistant A. baumannii strains. Follow-up experiments confirmed:
vi. Strong bactericidal activity
vii. Low cytotoxicity toward human cells

This case study highlights how AI can support the development of pathogen-specific antibiotics with improved precision and reduced off-target effects



Phage Lysins: AI-Guided Discovery (18)

Artificial intelligence has also been applied in the discovery of phage lysins, which are enzymes derived from bacteriophages that break down bacterial cell walls.

AI and machine learning models were trained using bacteriophage genomic data to recognize sequence patterns associated with lytic activity. These ML classifiers screened thousands of phage genomes and predicted novel lysins with strong antibacterial potential.

The identified lysins demonstrated broad-spectrum activity, particularly against Gram-positive bacterial pathogens. Experimental validation further confirmed their strong antibacterial effects.

This approach demonstrates how AI can explore previously uncharacterized genomic "dark matter" to identify entirely new antibacterial agents and therapeutic strategies.

Understanding AMR and Mechanism Prediction

AI for Predicting Resistance Mechanisms

The use of Artificial Intelligence (AI) models has increased significantly in understanding antimicrobial resistance (AMR) mechanisms. AI can analyze large datasets from genomic, transcriptomic, and proteomic studies to identify the genetic factors and biological

pathways underlying antibiotic resistance. This helps in the early detection and monitoring of newly emerging resistant bacterial strains.

Explainable Artificial Intelligence (XAI) techniques are increasingly used to improve the interpretability of predictions about antibiotic mechanisms of action (MOA). For example, hierarchical classifier models analyze transcriptomic changes to accurately identify the primary MOA of both known and novel compounds. Such approaches support rational antibiotic discovery and development.

In addition, AI models that integrate clinical and molecular data can predict the evolution of resistance patterns. These predictions provide valuable insights for developing effective therapeutic strategies in advance **(19)**

AI-Guided Identification of Novel Targets and Pathways

AI helps researchers identify new druggable targets in multidrug-resistant bacterial pathogens responsible for severe infections. By analyzing bacterial metabolic pathways and vulnerable cellular components, AI can determine the most critical targets for antibiotic action.

Multitarget AI models designed for multi-protein and multi-strain inhibition can address the complexity of resistance phenotypes. These models assist in the development of broad-spectrum antibiotics capable of overcoming multidrug resistance (MDR).

Furthermore, generative AI approaches can design novel molecular structures that bypass known resistance mechanisms. This is achieved by modifying structural features associated with bacterial efflux systems or enzymatic degradation, thereby improving antibiotic effectiveness **(20)**

Integration with Experimental and Clinical Data

For successful clinical application, AI-based discoveries must be supported by experimental validation. AI-assisted analysis of in vitro assays, such as Minimum Inhibitory Concentration (MIC) determination and time-kill studies, as well as in vivo experimental models, provides important insights into the efficacy and safety of antibiotic compounds.

The incorporation of real-world clinical data, including patient outcomes and resistance patterns, further improves the accuracy and predictive capability of AI models. Hybrid approaches that combine AI techniques with conventional experimental methods help overcome limitations such as model bias and prediction errors, thereby facilitating the translation of AI innovations into practical therapeutic applications.

Additionally, AI can rapidly process large healthcare datasets related to healthcare-associated infections, making it an effective tool for antimicrobial surveillance and stewardship programs



Figure 3. AMR and prediction of the mechanism with the help of AI

Challenges and Limitations of AI in Antibiotic Discovery

Technical and Methodological Barriers

One of the major challenges in AI-driven antibiotic discovery is the presence of imbalanced and noisy datasets. In many datasets, the number of active compounds or resistant bacterial variants is very small compared to inactive data, making it difficult to train highly accurate predictive models. To overcome this issue, advanced machine learning algorithms and data augmentation techniques are required.

Another important limitation is the lack of interpretability in AI models. Many deep learning systems function as "black boxes," where the decision-making process is not clearly understood. This reduces confidence among researchers, clinicians, and regulatory authorities.

In addition, biological systems are extremely complex. Antimicrobial resistance (AMR) often involves multiple genes, pathways, and environmental factors. Modeling such complexity requires high computational power and multi-scale analytical approaches.

Bias in training datasets is also a serious concern. Many AI models are mainly trained using data from Gram-positive bacteria, which limits their ability to accurately predict activity against Gram-negative pathogens. Consequently, some AI-predicted compounds fail during laboratory testing because of poor membrane permeability or susceptibility to bacterial efflux mechanisms **(21)**

Translational and Clinical Challenges

AI-generated predictions must be validated through both in vitro and in vivo experiments, which are costly and time-consuming. Although many compounds show promising computational results, they often fail during experimental validation.

Regulatory approval is another major obstacle. AI-discovered antibiotics must satisfy strict standards of safety, efficacy, and quality before they can be approved for clinical use. Furthermore, integrating AI technologies into conventional drug

discovery pipelines requires modifications in existing workflows, validation methods, and regulatory frameworks **(22)**

Socioeconomic and Infrastructure Constraints

AI-based antibiotic discovery depends heavily on advanced infrastructure, high-performance computing systems, and trained professionals. However, these resources are often limited in low- and middle-income countries, despite these regions being highly affected by antimicrobial resistance.

This imbalance creates inequality in access to advanced therapies and research opportunities. Therefore, greater investment in infrastructure, education, technical training, and global data-sharing initiatives is essential to ensure equitable progress in AI-driven healthcare **(23).**

Unanswered Questions and Knowledge Gaps

Despite rapid advancements in AI-assisted antibiotic discovery, several important challenges remain unresolved:

- Lack of explainability: AI models can predict antimicrobial activity, but they often cannot clearly explain the exact mechanism of action.
- Data scarcity versus novelty: AI systems require large datasets for training, whereas newly discovered compounds usually have very limited available data.
- Limited dynamic modeling: Most current models do not adequately account for real-time biological changes such as immune responses, metabolic variations, or drug–drug interactions.
- Resistance prediction: Predicting the future evolution of antimicrobial resistance remains highly challenging.
- Peptide drug limitations: Accurately predicting the toxicity, stability, and pharmacokinetic properties of antimicrobial peptides (AMPs) is still difficult.
- Multi-drug interactions: There is limited data and insufficient computational tools to reliably predict drug synergy and multi-target therapeutic effects **(23)**

Summary of AI's Role in Antibiotic Discovery

Artificial Intelligence (AI) has significantly transformed the process of antibiotic discovery. Earlier, most antibiotic research was performed manually or through trial-and-error methods, which were time-consuming, expensive, and less efficient. With the introduction of AI, the discovery process has become faster, more accurate, and more systematic.

AI technologies can analyze large amounts of chemical and biological data within a short period of time. They help researchers identify important molecular properties and design new molecules that are effective against antimicrobial resistance (AMR). This is highly important because drug-resistant bacteria are becoming a major global health threat.

AI also supports the discovery of different therapeutic agents such as natural products, antimicrobial peptides, and small molecules. This broadens the range of treatment options and improves the ability to target resistant microorganisms more effectively. As a result, drug development becomes quicker and more innovative.

Advanced AI techniques, including Machine Learning (ML), Deep Learning (DL), and generative models, play a major role in modern antibiotic discovery. These technologies can rapidly identify potential antibiotic candidates, predict their mechanism of action, and optimize their safety and efficacy. AI systems can also integrate data from multiple sources, such as genomics, proteomics, and chemical

libraries, to identify patterns that are difficult to detect using traditional methods.

Furthermore, AI improves important processes like virtual screening, Structure–Activity Relationship (SAR) analysis, and rational drug design. It helps in developing molecules with greater potency and fewer side effects. Successful examples such as Halicin and Abaucin demonstrate how AI can identify entirely new antibiotics effective against resistant bacteria.

In conclusion, AI reduces both the time and cost involved in antibiotic discovery and offers strong potential for future advancements in combating antimicrobial resistance.

Addressing Current Challenges

Although AI is a powerful tool in antibiotic discovery, several important challenges still exist.

The first challenge is the availability of high-quality data. AI models require accurate, complete, and standardized datasets for reliable predictions. Poor-quality, incomplete, or inconsistent data can lead to inaccurate outcomes. In addition, limited toxicity and resistance data reduce the effectiveness of prediction models. Therefore, better experimental methods and standardized databases are essential.

Another major issue is overfitting and poor generalization of AI models. Many models are trained on limited datasets and may fail when introduced to new or unseen data. As a result, their predictions may not always be reliable in real-world applications. Advanced approaches such as transfer learning and few-shot learning can improve model performance and adaptability.

The “black box” nature of many AI systems is another concern. Complex AI models, especially deep learning models, often provide predictions without explaining the reasoning behind them. This reduces trust in the results. To overcome this problem, Explainable Artificial Intelligence (XAI) techniques are required to make predictions more transparent and understandable for researchers and healthcare professionals.

Another challenge is the gap between computational predictions and actual biological results. Many compounds predicted by AI show promising results during computer simulations but fail during laboratory or clinical testing because biological systems are highly complex. Strong collaboration between computational scientists and experimental biologists is necessary to improve validation and reduce failure rates.

Ethical and economic concerns also need attention. High research costs, unequal access to technology, and limited data sharing can create global inequalities in healthcare research. Open-access databases, fair policies, international collaboration, and responsible AI practices are important for ensuring equal opportunities and the ethical use of AI in drug discovery.

Future Perspectives

The future of antibiotic discovery will largely depend on integrating AI with other advanced technologies such as synthetic biology, genomics, bioinformatics, and modern laboratory automation systems. This integration can further improve the speed, efficiency, and accuracy of discovering new antibiotics.

Interdisciplinary collaboration will play a crucial role in future developments. Researchers from fields such as computer science, microbiology, medicinal chemistry, pharmacology, and medicine must work together to build more effective AI models and validate their findings through experimental studies.

Funding agencies and research organizations should invest more in research infrastructure, open-access data platforms, and collaborative projects. Increased financial support will encourage innovation and accelerate the development of new antibiotics.

Governments and policymakers should also establish clear regulations and ethical guidelines for the safe and responsible use of AI in healthcare and pharmaceutical research. Proper regulation will help ensure transparency, patient safety, and fair use of AI technologies.

With strong international cooperation, open scientific collaboration, and continuous technological advancements, AI-based antibiotic discovery has the potential to become one of the most effective strategies for combating antimicrobial resistance and improving global healthcare systems.

References

1. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023 Jul 1;11(13). doi:10.3390/HEALTHCARE11131946 PubMed PMID: 37444780.
2. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals 2023, Vol 16,. 2023 Jun 18;16(6). doi:10.3390/PH16060891
3. Soori M, Arezoo B, Dastres R. Artificial intelligence, machine learning and deep learning in advanced robotics, a review. Cognitive Robotics. 2023 Jan 1;3:54–70. doi:10.1016/j.cogr.2023.04.001
4. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019 Jun 1;18(6):463–77. doi:10.1038/S41573-019-0024-5 PubMed PMID: 30976107.
5. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya A V., et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019 Sep 1;37(9):1038–40. doi:10.1038/S41587-019-0224-X PubMed PMID: 31477924.
6. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020 Feb 20;180(4):688-702.e13. doi:10.1016/j.cell.2020.01.021 PubMed PMID: 32084340.
7. Sanapalli BKR, Palit S, Deshpande A, Tokala R, Sigalapalli DK, Sanapalli V. Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and Clinical Translation. Antibiotics 2026, Vol 15,. 2026 Feb 23;15(2). doi:10.3390/ANTIBIOTICS15020233
8. Xu J, Li C, Wang X, Peleg AY, Li F, Song J, et al. Artificial intelligence in antibiotic discovery: Applications, challenges, and future outlook. Cell Biomaterials. 2026. doi:10.1016/j.celbio.2026.100445
9. Bilal H, Khan MN, Khan S, Shafiq M, Fang W, Khan RU, et al. The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance. Comput Struct Biotechnol J. 2025 Jan 1;27:423–39. doi:10.1016/j.csbj.2025.01.006
10. Huang D, Bai H, Wang L, Hou Y, Li L, Xia Y, et al. The Application and Development of Deep Learning in Radiotherapy: A Systematic Review. Technol Cancer Res Treat. 2021;20:15330338211016386. doi:10.1177/15330338211016386 PubMed PMID: 34142614.
11. Wouters OJ, McKee M, Luyten J. Research and Development Costs of New Drugs - Reply. JAMA - Journal of the

American Medical Association. 2020 Aug 4;324(5):518–9. doi:10.1001/JAMA.2020.8651 PubMed PMID: 32749488.

12. Szymczak P, Zarzecki W, Wang J, Duan Y, Wang J, Coelho LP, et al. AI-Driven Antimicrobial Peptide Discovery: Mining and Generation. Acc Chem Res. 2025 Jun 17;58(12):1831–46. doi:10.1021/ACS.ACCOUNTS.0C00594 PubMed PMID: 40459283.
13. Saleem N, Kumar N, El-Omar E, Willcox M, Jiang XT. Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides. Antibiotics 2025, Vol 14,. 2025 Dec 14;14(12). doi:10.3390/ANTIBIOTICS14121263
14. Hsiao Y, Su BH, Tseng YJ. Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. Brief Bioinform. 2021 May 1;22(3). doi:10.1093/BIB/BBAA160 PubMed PMID: 32770190.
15. Jorda A, Zeitlinger M. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review. Clinical Pharmacokinetics 2020 59:9. 2020 Apr 30;59(9):1071–84. doi:10.1007/S40262-020-00892-0 PubMed PMID: 32356105.
16. Ghaderzadeh M, Shalchian A, Irajian G, Sadeghsalehi H, Bialvaei AZ, Sabet B. Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review. Iranian Journal of Medical Microbiology. 2024;18(3):135–47. doi:10.30699/IJMM.18.3.135
17. Love MJ, Bhandari D, Dobson RCJ, Billington C. Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care. Antibiotics (Basel). 2018 Mar 1;7(1):1–25. doi:10.3390/ANTIBIOTICS7010017 PubMed PMID: 29495476.
18. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012 Oct;7(10):1147. doi:10.2217/FMB.12.97 PubMed PMID: 23030422.
19. Yang Y, Niehaus KE, Walker TM, Iqbal Z, Walker AS, Wilson DJ, et al. Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics. 2018 May 15;34(10):1666–71. doi:10.1093/BIOINFORMATICS/BTX801 PubMed PMID: 29240876.
20. Arango-Argoty G, Garner E, Pruden A, Heath LS, Vikesland P, Zhang L. DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. Microbiome. 2018;6(1). doi:10.1186/S40168-018-0401-Z PubMed PMID: 29391044.
21. Arús-Pous J, Johansson SV, Prykhodko O, Bjerrum EJ, Tyrchan C, Reymond JL, et al. Randomized SMILES strings improve the quality of molecular generative models. Journal of Cheminformatics 2019 11:1. 2019 Nov 21;11(1):71-. doi:10.1186/S13321-019-0393-0
22. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141). doi:10.1098/RSIF.2017.0387 PubMed PMID: 29618526.
23. Zhavoronkov A, Vanhaelen Q, Oprea TI. Will Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology? Clin Pharmacol Ther. 2020 Apr 1;107(4):780–5. doi:10.1002/CPT.1795 PubMed PMID: 31957003.